Nathaniel Scher
Papers
2
Total Citations
48
H-Index
2
About
Nathaniel Scher is a leading clinical researcher at the intersection of radiation oncology, health economics, and robotic surgery. His work focuses on optimizing treatment pathways for prostate cancer and other malignancies by rigorously comparing emerging technologies. Scher’s most cited study (41 citations) established the safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy (SBRT), demonstrating that CyberKnife tracking is both feasible and low-toxicity for extracranial tumors—a key validation for precision radiotherapy. In a landmark 2022 cost-utility analysis (7 citations), Scher directly compared robot-assisted radical prostatectomy against robotic SBRT for prostate cancer, integrating clinical outcomes with economic modeling to guide resource allocation in France’s healthcare system. This work is notable for bridging surgical and radiation oncology, providing evidence that helps clinicians and policymakers choose between two high-tech, costly interventions. By combining technical feasibility studies with health-economic evaluations, Scher’s research offers a comprehensive framework for value-based cancer care, influencing both clinical practice and reimbursement decisions. His contributions are essential reading for oncologists, surgeons, and health policy researchers seeking to balance innovation with cost-effectiveness.
Research Focus
Key Achievements
Top Papers
- 1
- 2